Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007

Bone Marrow Transplantation
Jm Goldman

Abstract

Whereas until 2000 allo-SCT was the recommended treatment for all new patients with CML who were eligible on grounds of age and donor availability, approaches to initial therapy have changed very substantially since the introduction of imatinib mesylate. Today topical questions are (1) Should any newly diagnosed patient receive SCT as primary therapy? (2) How should imatinib failure be defined? (3) Should a patient who has failed imatinib but is still in chronic phase be offered an SCT or further treatment with a 'second-generation' TKI? (4) Would prior treatment with imatinib or concomitant delay to transplant adversely affect the subsequent results of allo-SCT? (5) Once the decision to proceed with allo-SCT is taken, how exactly should this be performed? (6) If a patient relapses after allo-SCT, how should he/she be treated? These questions will be addressed, but definitive answers may not yet be possible.

References

Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Sep 13, 2003·Leukemia·E OlavarriaUNKNOWN Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT)
May 19, 2004·British Journal of Haematology·Jakob R PasswegUNKNOWN Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Apr 27, 2007·British Journal of Haematology·Sergio A GiraltUNKNOWN Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research

❮ Previous
Next ❯

Citations

Feb 6, 2010·Hematology·Guillermo J Ruiz-Argüelles
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Richard ChamplinMarcos de Lima
Mar 29, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Syed O A AhmedMahmoud Aljurf
Apr 2, 2009·Cancer Control : Journal of the Moffitt Cancer Center·Hugo F Fernandez, Mohamed A Kharfan-Dabaja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.